Effect of Aripiprazole on Methamphetamine-Induced Disruption of Latent Inhibition in Rats

Hisae Matsuo, Hiroshi Abe, Tetsuya Ikeda, Kosuke Ebihara, Ryuichiro Takeda, Toshikazu Nishimori, Yasushi Ishida

.
Department of Psychiatry, Faculty of Medicine, University of Miyazaki, 5200 Kihara,.

DOI: 10.4236/jbbs.2011.13022                

Abstract

Objectives: To elucidate the pharmacological profile of aripiprazole, we examined its ameliorating effect on the methamphetamine-induced disruption of latent inhibition (LI) in rats. Method: The effect was measured using a conditioned emotional response procedure. The conditioned stimulus was a tone (2.8 kHz, 90 dB), and the unconditioned stimulus was a mild foot shock delivered through a floor grid. The conditioning procedure was repeated five times. Results: Methamphetamine-induced (1.0 mg/kg, i.p.) disruption of LI was ameliorated by the administration of haloperidol (0.2 mg/kg, i.p.) and by a moderate dose of aripiprazole (0.3 mg/kg, i.p.) but not by a lower or higher dose (0.1 or 3.0 mg/kg, i.p.) of aripiprazole. However, immunohistochemical examination showed increased levels of c-Fos expression in the shell of the nucleus accumbens after the administration of haloperidol (0.2 mg/kg, i.p.) but not of aripiprazole (0.3 mg/kg, i.p.). Conclusions: It is suggested that aripiprazole has an ameliorating effect on methamphetamine-induced disruption of latent inhibition within only a marginal therapeutic window.

Keywords

Aripiprazole, Haloperidol, Latent Inhibition, c-Fos, Immunohistochemistry, Schizophrenia

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	I. Weiner, and M. Arad, “Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment,” Behavoral Brain Research, Vol. 204, No. 2, 2009, pp. 369-386.
[2]	R. E. Lubow, “Latent inhibition,” Psychological Bulletin, Vol. 79, No. 6, 1973, pp. 398-407.
[3]	G. Gosselin, P. Oberling, and G. Di Scala, “Antagonism of amphetamine-induced disruption of latent inhibition by the atypical antipsychotic olanzapine in rats,” Behavoural Pharmacology, Vol. 7, No. 8, 1996, pp. 820-826.
[4]	P. R. Solomon, A. Crider, J. W. Winkelman, A. Turi, R. M. Kamer and L. J. Kaplan, “Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity: relationship to schizophrenic attention disorder,” Biological Psychiatry, Vol. 16, No. 6, 1981, pp. 519-537.
[5]	E. C. Warburton, M. H. Joseph, J. Feldon, I. Weiner and J. A. Gray, “Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron,” Psychopharmacology (Berl), Vol. 114, No. 4, 1994, pp. 657-664.
[6]	I. Weiner, E. Shadach, R. Tarrasch, R. Kidron and J. Feldon, “The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic, clozapine,” Biological Psychiatry, Vol. 40, No. 9, 1996, pp. 834-843.
[7]	T. Kikuchi, K. Tottori, Y. Uwahodo, T. Hirose, T. Miwa, Y. Oshiro and S. Morita, “7-(4-[4-(2,3-Dichlorophenyl)- 1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-qui nolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity,” Journal of Pharmacology and Experimental Therapeutics, Vol. 274, No. 1, 1995, pp. 329-336.
[8]	R. A. Rivas-Vazquez, “Aripiprazole: A novel antipsychotic with dopamine stabilizing properties.,” Professional Psychology: Research and Practice, Vol. 34, No. 1, 2003, pp. 108-111.
[9]	S. Nakai, T. Hirose, T. Mori, A. Stark, H. Araki and T. Kikuchi, “The effect of aripiprazole on prepulse inhibition of the startle response in normal and hyperdopaminergic states in rats,” International Journal of Neuroscience, Vol. 118, No. 1, 2008, pp. 39-57.
[10]	G. Paxinos, and C. Watson, “The rat brain in stereotaxic coordinates,” Academic Press, San Diego, 1998.
[11]	B. Green, “Focus on aripiprazole,” Current Medical Research and Opinion, Vol. 20, No. 2, 2004, pp. 207-13.
[12]	G. S. Dawe, R. Nagarajah, R. Albert, D. E. Casey, K. W. Gross and A. K. Ratty, “Antipsychotic drugs dose- dependently suppress the spontaneous hyperactivity of the chakragati mouse,” Neuroscience, Vol. 171, No. 1, 2010, pp. 162-172.
[13]	M. Carli, E. Calcagno, P. Mainolfi, E. Mainini and R. W. Invernizzi, “Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex,” Psychopharmacology, Vol. 214, No. 3, 2010, pp. 639-652.
[14]	S. Nakai, T. Hirose, Y. Uwahodo, T. Imaoka, H. Okazaki, T. Miwa, M. Nakai, S. Yamada, B. Dunn, K. D. Burris, P. B. Molinoff, K. Tottori, C. A. Altar and T. Kikuchi, “Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone,” European Journal of Pharmacology, Vol. 472, No. 1-2, 2003, pp. 89-97.
[15]	S. Natesan, G. E. Reckless, J. N. Nobrega, P. J. Fletcher and S. Kapur, “Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models,” Neuropsychopharmacology, Vol. 31, No. 9, 2006, pp. 1854-63.